Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

M2ES 7.5mg

M2ES 15mg

M2ES 30mg

M2ES 45mg

Zhaosheng Li, MD

Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.

Phase I trail will be conducted to determine the MTD and safety of M2ES(administered intravenous infusion on Days 1,8,15,21of a 28-day cycle) in combination with gemcitabine (1000 m/m2). Gemcitabine will be administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle,at the same time determine the safety and efficiency of this combined regime.

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer

Protgen Ltd

Guodong Chang

M2ES 60mg

Su LI, PhD

Su Li, PhD

LI Zhang, master

Li Zhang, master

This study is dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

This study is a Phase I dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Pharmacokinetic (PK) behavior of different doses of M2ES in Subjects With Advanced Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer	NCT01218880	Pancreatic Canc...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 45mg	18 Years - 60 Years	Protgen Ltd
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors	NCT01226030	Advanced Solid ...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 60mg	18 Years - 65 Years	Protgen Ltd
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors	NCT01226030	Advanced Solid ...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 60mg	18 Years - 65 Years	Protgen Ltd
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer	NCT01218880	Pancreatic Canc...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 45mg	18 Years - 60 Years	Protgen Ltd

Spots Global Cancer Trial Database for m2es 7.5mg

Every month we try and update this database with for m2es 7.5mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for m2es 7.5mg

Every month we try and update this database with for m2es 7.5mg cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for m2es 7.5mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.